Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.50
NYSE:JNJ's Cash to Debt is ranked lower than
57% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. NYSE:JNJ: 1.50 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.63 Max: 6.28
Current: 1.5
0.46
6.28
Equity to Asset 0.52
NYSE:JNJ's Equity to Asset is ranked lower than
67% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.65 vs. NYSE:JNJ: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.52
0.5
0.67
Interest Coverage 28.02
NYSE:JNJ's Interest Coverage is ranked lower than
61% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.40 vs. NYSE:JNJ: 28.02 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.85 Max: 208.73
Current: 28.02
28.29
208.73
F-Score: 8
Z-Score: 5.11
M-Score: -2.49
WACC vs ROIC
7.23%
28.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 27.48
NYSE:JNJ's Operating margin (%) is ranked higher than
90% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. NYSE:JNJ: 27.48 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.43 Max: 28.2
Current: 27.48
22.36
28.2
Net-margin (%) 22.04
NYSE:JNJ's Net-margin (%) is ranked higher than
89% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.71 vs. NYSE:JNJ: 22.04 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 22.04
14.87
21.99
ROE (%) 21.88
NYSE:JNJ's ROE (%) is ranked higher than
87% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.47 vs. NYSE:JNJ: 21.88 )
Ranked among companies with meaningful ROE (%) only.
NYSE:JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 21.88
17.02
30.17
ROA (%) 11.55
NYSE:JNJ's ROA (%) is ranked higher than
84% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. NYSE:JNJ: 11.55 )
Ranked among companies with meaningful ROA (%) only.
NYSE:JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.55
8.93
17.08
ROC (Joel Greenblatt) (%) 101.70
NYSE:JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. NYSE:JNJ: 101.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 101.7
65.66
114.87
Revenue Growth (3Y)(%) 1.40
NYSE:JNJ's Revenue Growth (3Y)(%) is ranked lower than
62% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.2 Max: 14.8
Current: 1.4
1.4
14.8
EBITDA Growth (3Y)(%) 9.30
NYSE:JNJ's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.50 vs. NYSE:JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10 Max: 16.7
Current: 9.3
-6.6
16.7
EPS Growth (3Y)(%) 12.40
NYSE:JNJ's EPS Growth (3Y)(%) is ranked higher than
59% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 10.9 Max: 20.2
Current: 12.4
-8.6
20.2
» NYSE:JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 292,729 sh (unchged)
Michael Price 25,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Louis Moore Bacon Sold Out
Richard Snow 3,260 sh (-0.31%)
PRIMECAP Management 10,543,562 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

Diamond Hill Capital 1,969 sh (New)
David Rolfe 5,250 sh (New)
Jim Chanos 29,730 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Yacktman Fund 3,600,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,260 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 292,729 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Michael Price 25,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Jim Chanos 5,952 sh (unchged)
David Carlson 460,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Ray Dalio 129,700 sh (New)
Tom Russo 2,050 sh (New)
Louis Moore Bacon 3,552 sh (New)
Lee Ainslie 28,230 sh (New)
John Paulson 128,000 sh (New)
Jim Chanos 49,843 sh (+67.65%)
RS Investment Management 10,007 sh (+19.17%)
Jeremy Grantham 9,741,420 sh (+7.80%)
Diamond Hill Capital 2,110 sh (+7.16%)
Dodge & Cox 35,185 sh (+1.08%)
John Rogers 857,563 sh (+0.78%)
John Buckingham 63,881 sh (+0.38%)
Mairs and Power 2,185,819 sh (+0.03%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
John Hussman 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
David Rolfe 5,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Chuck Royce Sold Out
John Burbank Sold Out
Jeff Auxier 105,126 sh (-0.05%)
Ken Fisher 10,845,150 sh (-0.08%)
Murray Stahl 30,622 sh (-0.49%)
Richard Snow 3,220 sh (-1.23%)
Paul Tudor Jones 15,553 sh (-2.03%)
Tweedy Browne 3,216,513 sh (-4.93%)
Donald Yacktman 6,671,349 sh (-5.78%)
PRIMECAP Management 2,830,937 sh (-6.37%)
Manning & Napier Advisors, Inc 3,297,804 sh (-6.93%)
Richard Pzena 1,103,032 sh (-6.94%)
Ruane Cunniff 12,933 sh (-7.12%)
Mario Gabelli 312,831 sh (-7.33%)
Charles Brandes 133,128 sh (-8.97%)
Pioneer Investments 3,223,857 sh (-12.28%)
Barrow, Hanley, Mewhinney & Strauss 13,210,591 sh (-13.81%)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
Robert Olstein 41,000 sh (-18.00%)
First Eagle Investment 759,790 sh (-33.52%)
Sarah Ketterer 787,234 sh (-42.30%)
Jim Simons 626,100 sh (-73.70%)
Joel Greenblatt 4,906 sh (-97.97%)
» More
Q3 2016

JNJ Guru Trades in Q3 2016

Samuel Isaly 450,936 sh (New)
Joel Greenblatt 214,043 sh (+4262.88%)
Jim Simons 1,475,100 sh (+135.60%)
Paul Tudor Jones 28,124 sh (+80.83%)
Diamond Hill Capital 2,296 sh (+8.82%)
Pioneer Investments 3,454,669 sh (+7.16%)
John Rogers 858,549 sh (+0.11%)
Tweedy Browne Global Value 865,835 sh (unchged)
John Hussman 25,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Ken Fisher 10,845,620 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,250 sh (unchged)
Richard Perry Sold Out
Tom Russo Sold Out
Richard Snow 3,215 sh (-0.16%)
Dodge & Cox 34,985 sh (-0.57%)
T Rowe Price Equity Income Fund 3,380,000 sh (-0.59%)
Jeff Auxier 104,176 sh (-0.90%)
Mairs and Power 2,153,237 sh (-1.49%)
John Buckingham 62,429 sh (-2.27%)
Charles Brandes 126,627 sh (-4.88%)
Mario Gabelli 294,127 sh (-5.98%)
Murray Stahl 28,648 sh (-6.45%)
Barrow, Hanley, Mewhinney & Strauss 12,334,416 sh (-6.63%)
Lee Ainslie 26,320 sh (-6.77%)
Tweedy Browne 2,978,783 sh (-7.39%)
Yacktman Focused Fund 1,800,000 sh (-7.69%)
Donald Yacktman 6,143,753 sh (-7.91%)
Manning & Napier Advisors, Inc 3,028,532 sh (-8.17%)
Richard Pzena 1,002,314 sh (-9.13%)
Sarah Ketterer 705,335 sh (-10.40%)
PRIMECAP Management 2,519,397 sh (-11.00%)
Yacktman Fund 3,200,000 sh (-11.11%)
Louis Moore Bacon 2,875 sh (-19.06%)
Michael Price 20,000 sh (-20.00%)
Jeremy Grantham 7,282,964 sh (-25.24%)
Robert Olstein 30,000 sh (-26.83%)
Jim Chanos 35,387 sh (-29.00%)
Ruane Cunniff 5,713 sh (-55.83%)
Ray Dalio 44,400 sh (-65.77%)
John Paulson 35,000 sh (-72.66%)
First Eagle Investment 28,177 sh (-96.29%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:MRK, NYSE:NVS, NYSE:SNY, NYSE:ABBV, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Ratios

vs
industry
vs
history
P/E(ttm) 19.82
JNJ's P/E(ttm) is ranked higher than
65% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.64 vs. JNJ: 19.82 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 19.82
10.5
24
Forward P/E 15.53
JNJ's Forward P/E is ranked lower than
52% of the 94 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.71 vs. JNJ: 15.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.82
JNJ's PE(NRI) is ranked higher than
68% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.23 vs. JNJ: 19.82 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 19.82
10.5
24
Price/Owner Earnings (ttm) 21.88
JNJ's Price/Owner Earnings (ttm) is ranked higher than
67% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.83 vs. JNJ: 21.88 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.56 Max: 25.26
Current: 21.88
10.19
25.26
P/B 4.19
JNJ's P/B is ranked lower than
68% of the 953 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. JNJ: 4.19 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 4.99
Current: 4.19
2.68
4.99
P/S 4.37
JNJ's P/S is ranked lower than
65% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. JNJ: 4.37 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.95
Current: 4.37
2.17
4.95
PFCF 23.34
JNJ's PFCF is ranked lower than
54% of the 270 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.85 vs. JNJ: 23.34 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.56 Max: 24.88
Current: 23.34
10.28
24.88
POCF 18.51
JNJ's POCF is ranked lower than
55% of the 362 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.38 vs. JNJ: 18.51 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.23 Max: 19.85
Current: 18.51
8.98
19.85
EV-to-EBIT 14.60
JNJ's EV-to-EBIT is ranked higher than
65% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.57 vs. JNJ: 14.60 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.9 Max: 18.2
Current: 14.6
7.8
18.2
EV-to-EBITDA 12.30
JNJ's EV-to-EBITDA is ranked higher than
64% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. JNJ: 12.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.9 Max: 14.8
Current: 12.3
6.7
14.8
PEG 3.36
JNJ's PEG is ranked lower than
65% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. JNJ: 3.36 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 1.76 Max: 25.96
Current: 3.36
1.17
25.96
Shiller P/E 22.75
JNJ's Shiller P/E is ranked higher than
76% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.34 vs. JNJ: 22.75 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.52  Med: 20.81 Max: 28.83
Current: 22.75
15.52
28.83
Current Ratio 2.73
JNJ's Current Ratio is ranked higher than
56% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. JNJ: 2.73 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.08 Max: 3.08
Current: 2.73
1.2
3.08
Quick Ratio 2.36
JNJ's Quick Ratio is ranked higher than
61% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. JNJ: 2.36 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.72 Max: 2.68
Current: 2.36
0.94
2.68
Days Inventory 138.61
JNJ's Days Inventory is ranked lower than
61% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.87 vs. JNJ: 138.61 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.61
100.19
137.6
Days Sales Outstanding 60.15
JNJ's Days Sales Outstanding is ranked higher than
65% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.59 vs. JNJ: 60.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 60.15
53.94
61.4
Days Payable 99.86
JNJ's Days Payable is ranked higher than
68% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.65 vs. JNJ: 99.86 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 99.86
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.80
JNJ's Dividend Yield is ranked higher than
73% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.80 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 2.04  Med: 2.84 Max: 3.84
Current: 2.8
2.04
3.84
Dividend Payout 0.54
JNJ's Dividend Payout is ranked lower than
71% of the 390 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.43 Max: 6.33
Current: 0.54
0.29
6.33
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
52% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.87
JNJ's Forward Dividend Yield is ranked higher than
72% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.87 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.93
JNJ's Yield on cost (5-Year) is ranked higher than
74% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. JNJ: 3.93 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.86  Med: 3.98 Max: 5.39
Current: 3.93
2.86
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 434 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.70 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.1 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.88
JNJ's Price/Tangible Book is ranked lower than
91% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. JNJ: 13.88 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.44 Max: 18.92
Current: 13.88
6.24
18.92
Price/Projected FCF 1.57
JNJ's Price/Projected FCF is ranked higher than
69% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. JNJ: 1.57 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.86  Med: 1.4 Max: 3.6
Current: 1.57
0.86
3.6
Price/DCF (Earnings Based) 1.85
JNJ's Price/DCF (Earnings Based) is ranked lower than
64% of the 103 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. JNJ: 1.85 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.36
JNJ's Price/Median PS Value is ranked lower than
66% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. JNJ: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.16 Max: 1.88
Current: 1.36
0.74
1.88
Price/Peter Lynch Fair Value 2.07
JNJ's Price/Peter Lynch Fair Value is ranked lower than
63% of the 177 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.07 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.2  Med: 1.89 Max: 4.03
Current: 2.07
1.2
4.03
Price/Graham Number 3.50
JNJ's Price/Graham Number is ranked lower than
74% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. JNJ: 3.50 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.19 Max: 5.97
Current: 3.5
1.97
5.97
Earnings Yield (Greenblatt) (%) 6.80
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 1015 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. JNJ: 6.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.8 Max: 12.9
Current: 6.8
5.5
12.9
Forward Rate of Return (Yacktman) (%) 13.99
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 340 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.22 vs. JNJ: 13.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 13.8 Max: 18.6
Current: 13.99
1.8
18.6

More Statistics

Revenue (TTM) (Mil) $71,595
EPS (TTM) $ 5.65
Beta0.69
Short Percentage of Float0.72%
52-Week Range $94.28 - 126.07
Shares Outstanding (Mil)2,720.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 72,064 75,838 78,209
EPS ($) 6.64 7.17 7.52
EPS w/o NRI ($) 6.64 7.17 7.52
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
Dividends Per Share ($) 3.14 3.35 3.54
» More Articles for NYSE:JNJ

Headlines

Articles On GuruFocus.com
Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
US Market Indexes Lower to Start the Week Nov 28 2016 
Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy Nov 28 2016 
Small-Cap Biotech Is on Front Lines of Fight Against Depression Nov 22 2016 
Richard Perry Exits AIG, Time Warner Nov 14 2016 
RA Drug Comparison Yields Mixed Results Nov 14 2016 
Johnson & Johnson Expect it to Deliver Consistent Results Nov 08 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Dividend Aristocrats in Focus Part 24: Johnson & Johnson Nov 01 2016 
AbbVie Reports 3rd Quarter Results Nov 01 2016 

More From Other Websites
J&J Plans to Appeal Staggering $1B Judgment Against Hip Implant Dec 02 2016
J&J’s Raised Offer for Actelion Said North of $250 a Share Dec 02 2016
Actelion's silence has hedge funds betting big on J&J deal Dec 02 2016
Actelion's silence has hedge funds betting big on J&J deal Dec 02 2016
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche Dec 02 2016
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
5 Things You Must Know Before the Market Opens Friday Dec 02 2016
Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
Dallas Jury Returns $1 Billion-Plus Verdict in Defective DePuy Hip Implants Lawsuit Dec 01 2016
Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
Johnson & Johnson hit with over $1 bln verdict on hip implants Dec 01 2016
J&J Ordered to Pay $1 Billion for Faulty Hip Implants Dec 01 2016
J&J Ordered to Pay Record $1 Billion for Faulty Hip Implants Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)